financetom
Business
financetom
/
Business
/
CrowdStrike Q1 Earnings: Revenue, EPS Miss Estimates, Cybersecurity Company Raises FY26 Guidance, Approves $1B Buyback
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CrowdStrike Q1 Earnings: Revenue, EPS Miss Estimates, Cybersecurity Company Raises FY26 Guidance, Approves $1B Buyback
Jun 3, 2025 2:13 PM

CrowdStrike Holdings Inc ( CRWD ) reported first-quarter financial results after the market close on Tuesday. Here’s a rundown of the report.

Q1 Earnings: CrowdStrike ( CRWD ) reported first-quarter revenue of $1.10 billion, missing analyst estimates of $1.16 billion, according to Benzinga Pro. The cybersecurity company reported adjusted earnings of 73 cents per share, missing analyst estimates of 81 cents per share.

Total revenue was up 20% year-over-year in the first quarter, and subscription revenue also grew 20% to $1.05 billion. Annual recurring revenue increased 22% year-over-year to $4.44 billion after the company added $193.8 million of net new ARR in the quarter.

Net cash generated from operations was $384.1 million and free cash flow came in at $279.4 million. The company ended the quarter with $4.61 billion in cash, equivalents and short-term investments.

“We started the fiscal year with record Q1 large deal and MSSP momentum alongside sustained 97% gross retention and consistently strong net retention as the market consolidates on Falcon as its cybersecurity platform of choice for the agentic AI era,” said George Kurtz, co-founder, president and CEO of CrowdStrike ( CRWD ).

“The scale of Falcon Flex demand and the pace of innovation across AI, next-gen SIEM, cloud, identity, and exposure management advances us towards $10 billion in ending ARR.”

CrowdStrike’s board approved a share repurchase program of up to $1 billion.

Outlook: CrowdStrike ( CRWD ) expects second-quarter revenue to be between $1.145 billion and $1.152 billion versus estimates of $1.23 billion. The company anticipates second-quarter adjusted earnings of 82 cents to 84 cents per share versus estimates of 92 cents per share.

CrowdStrike ( CRWD ) also raised its full-year guidance. The company now expects full-year revenue of $4.74 billion to $4.81 billion versus estimates of $4.77 billion. The company also raised its full-year adjusted earnings guidance from a range of $3.33 to $3.45 per share to a new range of $3.44 to $3.56 per share versus estimates of $3.43 per share.

CrowdStrike’s management team will further discuss the company’s quarterly results on a conference call with investors and analysts at 5 p.m. ET.

CRWD Price Action: CrowdStrike ( CRWD ) shares were down 7.31% after-hours, trading at $453.02 at the time of publication on Tuesday, according to Benzinga Pro.

Read Next:

Small Caps Surge, Dollar General Stock Eyes Best Day, Crude Hits 2-Week Highs: What’s Driving Markets Tuesday?

EXCLUSIVE: May’s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Schrodinger Drug Gets FDA Fast Track for Rare Blood Cancer Treatment
Schrodinger Drug Gets FDA Fast Track for Rare Blood Cancer Treatment
Jun 27, 2025
08:35 AM EDT, 06/27/2025 (MT Newswires) -- Schrodinger (SDGR) said Friday the US Food and Drug Administration has granted fast track designation to SGR-1505 for treating relapsed or refractory Waldenstrom macroglobulinemia, a rare form of blood cancer. The treatment targets adult patients who have failed at least two prior therapies, including a Bruton's tyrosine kinase inhibitor, the company said. SGR-1505...
Vnet Approves $50 Million Buyback Program; Shares Up Pre-Bell
Vnet Approves $50 Million Buyback Program; Shares Up Pre-Bell
Jun 27, 2025
08:35 AM EDT, 06/27/2025 (MT Newswires) -- Vnet Group ( VNET ) said Friday its board has authorized a share buyback program under which the company may repurchase up to $50 million of its American depositary shares. Each American depositary shares represents six class A ordinary shares of the company. The company said it expects to utilize its existing funds...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says
Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says
Jun 27, 2025
08:33 AM EDT, 06/27/2025 (MT Newswires) -- Biogen's (BIIB) potential Alzheimer's disease drug Leqembi has meaningful advantages over Eli Lilly's ( LLY ) Kisunla that could help surpass its rival, RBC Capital Markets said in a note to investors on Friday. While Kisunla is being developed and tested more quickly, Leqembi's subcutaneous administration and cleaner safety could help it gain...
Copyright 2023-2026 - www.financetom.com All Rights Reserved